Loading
Cemiplimab shrank tumours in about half of patients with metastatic or locally advanced cutaneous squamous cell carcinoma, a highly mutated skin cancer with almost no previous treatment options, leading to the first approval for the disease.
Phase 1 expansion cohort (26 patients) and phase 2 study (59 patients) of cemiplimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma not amenable to curative surgery or radiotherapy.
Objective response was 50 percent in the phase 1 cohort and 47 percent in the phase 2 metastatic cohort, with most responses durable beyond six months and typical immune-related toxicity.
PD-1 blockade is the first-line systemic treatment for advanced cutaneous squamous cell carcinoma, including on the lip, and cemiplimab has since moved into neoadjuvant and adjuvant use.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares EMPOWER-CSCC-1, Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares EMPOWER-CSCC-1, Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/